Español


5/3/21
Orladeyo Approved in EU as 1st Oral Treatment to Prevent HAE Attacks

4/29/21
Supporters ‘Take Next Step’ Toward HAE Awareness Day on May 16

4/23/21
Prophylactic treatment in hereditary angioedema is associated with reduced anxiety in patients in Leipzig, Germany

4/19/2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

4/13/2021
Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study

4/12/2021
Life Quality Gains Evident With Newer Preventive HAE Therapies, Survey Finds

3/29/2021
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema

3/26/2021
COVID-19 as a trigger of acute attacks in people with hereditary angioedema

3/22/2021
Intellia Seeks to Advance Its Gene-editing Therapy to Human Trials

3/18/2021
Orladeyo Now Available in France Via Early Access Program

3/17/2021
Patient-researcher Collaboration Proves To Be A Win-win, Japanese Study Shows

3/12/2021
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks

3/11/2021
Recurrent and acute abdominal pain as the main clinical manifestation in patients with hereditary angioedema

3/11/2021
Screening for Plasminogen Mutations in Hereditary Angioedema Patients Genes Article MDPI

3/11/2021
Biocryst’s berotralstat granted early access for HAE in France

3/11/2021
Orphan product designation requests climb in the US, remain steady in the EU

3/11/2021
First Patient Dosed in Phase 2 Trial Testing PHVS416 for HAE Attacks

3/08/2021
Interim Trial Data of Gene-editing Therapy NTLA-2001 Expected This Year

3/05/2021
Long-term Haegarda Found to Improve Quality of Life in HAE Patients

3/03/2021
BioCryst Pharma (BCRX) Submits MAA for UK Approval of ORLADEYO, an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema

3/01/2021
Orladeyo Recommended in EU as 1st Oral Treatment to Prevent HAE Attacks

2/26/2021
Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers

2/25/2021
Oral Hereditary Angioedema Treatment Provides Effective Bradykinin-Inhibiting Concentrations

2/23/2021
C1 Inhibitor Use May Safely Prevent HAE Attacks in Pregnant Women

2/19/2021
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting

2/18/2021
HAE Patients in US Favored Oral Prophylactic in 2018 Survey

2/15/2021
Stress Can Affect Patients' Mental Health, How They Manage Their Care

2/08/2021
Menopause Found to Not Worsen HAE in Most Women

2/08/2021
Optimal Management of HAE: Shared Decision Making

1/09/2021
Psychological processes in the experience of hereditary angioedema in adult patients: an observational study

11/01/2020
HAE Primer

9/29/2021
Haegarta Pediatric Release

9/01/2020
Medical Advisory Board Guidelines 2020

11/01/2016
Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency